Part of CSL Ltd., Vifor (International) AG is a Swiss company located in St. Gallen. The firm develops, manufactures and supplies pharmaceutical products.

Pharmacosmos Holding A/S conducts business with the development of pharmaceutical, chemical, and technical products and processes. It also acquires, owns, and administers rights in connection therewith; and to own shares in companies engage in the development, production, and trade of pharmaceutical, chemical, and technical products. The company was founded on October 12, 1965 and is headquartered in Holbaek, Denmark.

Shield TX (UK) Ltd., a subsidiary of Maru AG, is a company headquartered in Gateshead, UK. The firm provides clinical trials. It was founded in 2008.

Kellogg Company, with its global headquarters in Battle Creek, Michigan, USA, is the world's leading cereal company, and a major producer of convenience foods. It markets more than 1,500 products in over 180 countries all over the world. Founded in 1906, with a commitment to nutrition, Kellogg Company has always been focusing on its products and processes. Today, with more than 100 ready-to-eat cereals around the world, consumers count on Kellogg for providing great-tasting, convenient and healthy food choices that meet their nutrition needs. Kellogg entered India in 1995 and during these 16 years, the company has become synonymous with great tasting & nourishing breakfast cereals. With a range of brands appealing to kids, adults and of course, the entire family, Kellogg's is becoming a common feature on breakfast tables across Indian homes today.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Keryx Biopharmaceuticals is a biopharmaceutical company that is focused on the development and commercialization of medicines for chronic kidney diseases. Keryx Biopharmaceuticals offers Auryxia, a medicine that is able to lower the amount of phosphate in blood. It supports investigator sponsored research conducted by independent researchers with Auryxia. It facilitates programs such as Reimbursement Help, Copay Program, and Patient Assistance. Keryx Biopharmaceuticals was founded in October 1998 and is based in New York.

Fe3 Medical Inc. engages in commercialization of a drug delivery technology that enables the safe, non-toxic transport of approximately 10 milligrams of iron across the skin for those who suffer with iron-deficiency anemia.

FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

Zhejiang Cnb Health Products Co., Ltd. is a company headquartered in Hangzhou, China, that operates as a biotechnology company.

Shandong Sibangde Pharmaceutical Co., Ltd., established on 2003-10-22, Business range includes tablet,Manufacture of hard capsules.(The above projects shall be operated within the operating period approved by the examination and approval authority)computer software development.(subject to approval,Do not operate without approval)

Intrinsic LifeSciences LLC, a life sciences company, develops in vitro diagnostic devices for clinical medicine applications. It focuses on the development of diagnostic tests and biomarker panels for the diagnosis of genetic and acquired iron disorders, including congential anemias, hemochromatosis, and inflammatory diseases in which iron homeostasis is dysregulated. The company also develops biological therapeutics, as well as hepcidin assays for measuring hepcidin; performs hepcidin assays for pharmaceutical companies and clinical investigators worldwide; and provides clinical research services. In addition, it offers hepcidin products, including kits, common reagents, specific reagents, hepcidin murine-compete, mouse hepcidin-1 peptide standard solutions, mouse hepcidin-1 biotin conjugates, sample diluents, SA-HRP conjugates, wash solutions, TMB substrates, and stop solutions online. The company was founded in 2006 and is based in La Jolla, California.

Morinaga Milk Industry Co., Ltd. engages in the production and distribution of dairy products. Its operations are carried out through the following segments: Food Products and Others. The Food Products segment engages in the production and sale of milk, dairy-based beverages, yogurt, desserts, condensed milk, powdered milk, butter, cheese, ice cream, non-dairy beverages (juice, tea, coffee), and clinical liquid diets. The Others segment provides the real estate leasing services. It also engages in the manufacture and sale of animal feeds; design and construction of plant equipment. The company was founded on September 1, 1917 and is headquartered in Tokyo, Japan.

Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to enter for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.

Nippon Zoki Pharmaceutical Co. Ltd. is a private company headquartered in Chuo-ku, Japan, that manufactures pharmaceutical products.

Novartis Animal Health is a leader in developing new and better ways to prevent and treat diseases in pets, farm animals and farmed fish. Their innovative, high-quality medicines contribute to the quality of life, health and welfare of animals around the world. They focus on developing new products and technologies to meet the diverse needs of pet owners, veterinarians, farmers and fish farmers now and in the future. Their scientists strive to improve animal care and welfare by researching new medicines and novel drug delivery technologies to improve efficacy and ease of use.

The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.